Cite
HARVARD Citation
Long, G. et al. (2022). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet oncology. 23 (11), pp. 1378-1388. [Online].